Apremilast Prolongs the Time to First Biologic Therapy in Japanese Patients with Psoriasis

Objective: The aim of the study was to improve understanding of adherence and persistence to biologics, and their association with health-care resource utilization (HCRU), in Japanese patients with moderate to severe ulcerative colitis (UC). Methods: Data were from Medical Data Vision, a secondary care administrative database. A retrospective, longitudinal cohort analysis was conducted of data from UC patients initiating biologic therapy between August 2013 and July 2016. Data collected for 2 years prior (baseline) and 2 years after (follow-up) the index date were evaluated. Patients completing biologic induction were identified, and adherence/persistence to biologic therapy calculated. HCRU, steroid, and immunosuppressant use during baseline and follow-up were assessed. Biologic switching during the follow-up was evaluated. Descriptive statistics (e.g., means and proportions) were obtained and inferential analyses (from Student’s t tests, Fisher’s exact tests, χ2 tests, the Cox proportional hazard model, and negative binomial regression) were performed. Results: The analysis included 649 patients (adalimumab: 265; infliximab: 384). Biologic induction was completed by 80% of patients. Adherence to adalimumab was higher than that to infliximab (p < 0.001). Persistence at 6, 12, 18, and 24 months was higher with infliximab than with adalimumab (p < 0.05). Overall, gastroenterology outpatient visits increased, and hospitalization frequency and duration decreased, from baseline to follow-up. UC-related hospitalizations were fewer and shorter, and endoscopies fewer, in persistent than in nonpersistent patients, although persistent patients made more outpatient visits than nonpersistent patients. Hospitalization duration was lower in persistent than nonpersistent patients. Approximately 50% of patients received an immunosuppressant during biologic therapy; 5% received a concomitant steroid during biologic therapy. Overall, 17% and 3% of patients, respectively, received 2nd line and 3rd line biologics. Conclusions: Poor biologic persistence was associated with increased non-medication-associated HCRU. Effective treatments with high persistence levels and limited associated HCRU are needed in UC.

Download Full-text

AB0666 Clinical Significance of Hypocomplementemia in Japanese Patients with Rheumatoid Vasculitis in the Era of Biologic Therapy

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-eular.5378 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 1121.2-1121

Author(s):

T. Zoshima ◽

I. Mizushima ◽

K. Yamada ◽

M. Kawano

Keyword(s):

Clinical Significance ◽

Biologic Therapy ◽

Japanese Patients ◽

Rheumatoid Vasculitis

Download Full-text

Factors Affecting Postoperative Recurrence in Japanese Patients With Crohnʼs Disease in The Era of Biologic Therapy: Retrospective Single Center Study

Inflammatory Bowel Diseases ◽

10.1097/00054725-201212001-00159 ◽

2012 ◽

Vol 18 ◽

pp. S65-S66

Author(s):

Motohiro Esaki ◽

Takayuki Matsumoto ◽

Junji Umeno ◽

Kouichi Asano ◽

Tomohiko Moriyama ◽

...

Keyword(s):

Biologic Therapy ◽

Japanese Patients ◽

Postoperative Recurrence ◽

Single Center ◽

Factors Affecting ◽

Single Center Study ◽

Center Study

Download Full-text

Clinical Investigation of Nontuberculous Mycobacterial Lung Disease in Japanese Patients with Rheumatoid Arthritis Receiving Biologic Therapy

The Journal of Rheumatology ◽

10.3899/jrheum.130511 ◽

2013 ◽

Vol 40 (12) ◽

pp. 1994-2000 ◽

Cited By ~ 8

Author(s):

Hideaki Yamakawa ◽

Noboru Takayanagi ◽

Takashi Ishiguro ◽

Tetsu Kanauchi ◽

Toshiko Hoshi ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Lung Disease ◽

Biologic Therapy ◽

Clinical Investigation ◽

Japanese Patients ◽

Radiological Outcome ◽

Disease Extent ◽

Nontuberculous Mycobacterial Lung Disease ◽

High Erythrocyte Sedimentation Rate ◽

Ntm Lung Disease

Objective.To review patients with rheumatoid arthritis (RA) receiving biologic therapy following a diagnosis of nontuberculous mycobacterial (NTM) lung disease and to evaluate disease deterioration according to clinical and radiological features and anti-NTM therapy.Methods.We retrospectively analyzed medical records of 11 human immunodeficiency virus-negative patients with RA (median age, 64 years) receiving biologic therapy following diagnosis of NTM lung disease.Results.NTM species included Mycobacterium avium complex in 9 patients (81.8%) and M. gordonae in 2 (18.2%). Underlying respiratory disease was present in 6 patients (54.5%), and most (81.8%) had radiographic features of nodular/bronchiectatic disease. Extent of NTM disease was 1–2 pulmonary lobes in 6 patients (54.5%), 3–4 lobes in 5 patients (45.5%), and 5–6 lobes in none. The results of radiological evaluations were unchanged or improved in 7 patients (63.6%) and worsened in 4 (36.4%). Radiological outcome was worse in patients with poor RA control despite their receiving biologic therapies for RA. Two of 3 patients receiving anti-NTM therapy as initial management for NTM improved, and 1 worsened. Three of 4 patients with worsened radiological outcome had high erythrocyte sedimentation rate (> 50 mm/h).Conclusion.Radiological deterioration was not observed in the majority of patients with RA receiving biologic therapy with NTM lung disease, and radiological outcome of pulmonary NTM was favorable in some patients undergoing anti-NTM therapy. Further studies focusing on disease deterioration according to biologic therapy received during NTM followup are warranted to determine appropriate treatment of RA patients with NTM lung disease.

Download Full-text